TICKERNERD
Menu
APREAPREHealthcare · Biotechnology

APRE Stock Forecast: Aprea Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$0.78
+0.96% on the day

The 3 Wall Street analysts covering Aprea Therapeutics, Inc. hold a median 12-month price target of $5 — +539.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 14 Sept 2026 — in the lower half.

Market cap
$9.8M
Ticker Nerd rank
46 / 100
Median analyst target
$5.00
Analysts covering
3
Revenue$0.0
Operating income−$4.0M
Net income−$3.6M
Free cash flow−$3.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.6%
1M
+14.9%
YTD
−8.4%
1Y
−49.4%
From 52W high
−52.6%
From 52W low
+32.4%
$0.59
$1.65
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

APRE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aprea Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
46 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
93
Growth
83
Revisions
67
Quality
55
Volatility
47
Accruals
33
Momentum
29
Issuance
28
Value
10

Size (93): Smaller than most of the companies we track.

Value (10): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

APRE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APRE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26APREHigh $5.00Median $5.00Low $1.20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $1.20Median $5.00High $5.00

The green dot is the last close — the median target sits +539.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026WedbushMaintainsOutperform$6.00 → $3.00
14 May 2026WedbushMaintainsOutperform$7.00 → $6.00
14 May 2026WedbushMaintainsOutperform—
7 May 2026OppenheimerInitiatesOutperform$5.00
7 May 2026OppenheimerInitiatesOutperform—
31 Mar 2026HC Wainwright & Co.MaintainsBuy—
31 Mar 2026WedbushReiteratesOutperform—
10 Feb 2026WedbushMaintainsOutperform—
29 Jan 2026HC Wainwright & Co.MaintainsBuy—
18 Dec 2025HC Wainwright & Co.MaintainsBuy—
15 Jan 2025HC Wainwright & Co.ReiteratesBuy—
17 Dec 2024HC Wainwright & Co.ReiteratesBuy—
18 Nov 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—
13 Aug 2024WedbushReiteratesOutperform—
12 Aug 2024HC Wainwright & Co.ReiteratesBuy—
24 June 2024HC Wainwright & Co.ReiteratesBuy—
17 June 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
27 Mar 2024WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APRE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

APRE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Aprea Therapeutics, Inc. returned −49.4% against +17.0% for the S&P 500, dividends included.

APRE vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26APRES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

APRE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Aprea Therapeutics, Inc. (APRE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.5×

Cheaper than 71% of US stocks

Price / sales
1897.5×

Cheaper than 1% of US stocks

Price / book
0.3×

Cheaper than 89% of US stocks

EV / EBITDA
2.3×

Cheaper than 56% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−255025.5%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−46.1%

Higher than 22% of US stocks

Return on assets
−27.7%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aprea Therapeutics, Inc. (APRE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aprea Therapeutics, Inc. has a market value of $9.8M and an enterprise value of −$30.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$12.3M.

  • Diluted earnings per share, trailing twelve months: $−1.08.

  • Free cash flow in the twelve months to 30 June 2026: −$12.2M.

  • Shares outstanding: 12.4M.

  • Trailing P/E: 0.5×; forward P/E: −2.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Aprea Therapeutics, Inc. employs 8 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

APRE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
APREAprea Therapeutics, Inc.$9.8M
46
LNAILunai Bioworks, Inc.$9.8M
34
XBIOXenetic Biosciences, Inc.$9.9M
39
SNTISenti Biosciences Holdings, Inc.$9.4M
54
ENSCEnsysce Biosciences, Inc.$9.4M
37
KALAKala Bio, Inc.$10.1M
15
GDTCCytoMed Therapeutics Ltd.$10.1M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aprea Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest APRE news & analysis

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 10 Sept 2026neutral

Aprea Therapeutics announced that its President and CEO, Oren Gilad, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference, held in person and virtually from September 14-16, 2026. The announcement was made on September 10, 2026, from the company's headquarters in Doylestown, Pennsylvania.

Why it matters — APRE watchers may be interested because the company's leadership will have a platform to present its clinical-stage oncology pipeline to the investment community at a major industry conference.

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

GlobeNewsWire · 28 Aug 2026positive

Aprea Therapeutics announced an expansion of its intellectual property portfolio for its precision oncology programs, now holding 28 issued and 30 pending patents globally. The company stated the expansion strengthens its global intellectual property position.

Why it matters — An expanded patent portfolio could help protect Aprea's proprietary oncology programs and strengthen its competitive position in the precision oncology space.

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

GlobeNewsWire · 12 Aug 2026positive

Aprea Therapeutics announced its second quarter 2026 financial results. The company reported that enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances.

Why it matters — APRE watchers would care because accelerating enrollment signals continued momentum for the company's lead clinical program, APR-1051.

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

GlobeNewsWire · 30 July 2026positive

Aprea Therapeutics provided an update on the ongoing Phase 1 dose escalation ACESOT-1051 trial of its WEE1 inhibitor APR-1051, reporting accelerating enrollment and plans to expand the drug's evaluation into uterine serous carcinoma, platinum-resistant ovarian cancer, HPV-positive head and neck cancer, and colorectal cancer. The company anticipates presenting the next clinical data update at a medical meeting in Q4 2026.

Why it matters — APRE watchers would care because the company is signaling continued clinical progress and an expanded development strategy for APR-1051, its lead pipeline candidate, with a key data catalyst expected in late 2026.

FAQ

Frequently asked questions about APRE stock

What is the APRE stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Aprea Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $1.2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APRE stock a buy right now?

Of the 3 analysts covering Aprea Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aprea Therapeutics, Inc. 46 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APRE?

As at 14 Sept 2026, Aprea Therapeutics, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

Will APRE stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +539.9% from the last close, and Ticker Nerd's factor model ranks Aprea Therapeutics, Inc. 46 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APRE stock forecast for 2030?

No analyst covering Aprea Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.2 to $5 over the next 12 months.

How has APRE stock performed over the past year?

Aprea Therapeutics, Inc. returned -49.4% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aprea Therapeutics, Inc. do?

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology and biomarker-defined cancers.

What is the latest news on APRE?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference". Aprea Therapeutics announced that its President and CEO, Oren Gilad, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference, held in person and virtually from September 14-16, 2026. The announcement was made on September 10, 2026, from the company's headquarters in Doylestown, Pennsylvania.

Company

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology and biomarker-defined cancers. The company develops targeted cancer therapies designed to exploit DNA damage response and synthetic lethality pathways, aiming to address vulnerabilities in tumor cells while limiting impact on healthy tissue. Its current pipeline centers on investigational small-molecule programs, including APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both being evaluated in clinical development for solid tumor indications. Aprea Therapeutics concentrates on oncology research and drug development for cancers with high unmet medical need, supporting its role in the broader market for targeted and precision medicine therapeutics. The company is headquartered in Doylestown, Pennsylvania.

CEO Dr. Oren Gilad Ph.D. · 8 employees · United States · https://aprea.com